EDGAR Filing Documents for 0001104659-16-159611

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:

SEC Accession No. 0001104659-16-159611

Filing Date

2016-11-29

Accepted

2016-11-29 16:36:34

Documents

Period of Report

2016-11-29

Document Format Files

Seq	Description	Document	Type	Size
1	6-K	a16-22208_16k.htm	6-K	29439
2	EX-8.1	a16-22208_1ex8d1.htm	EX-8.1	12694
3	EX-8.2	a16-22208_1ex8d2.htm	EX-8.2	61289
4	EX-99.1	a16-22208_1ex99d1.htm	EX-99.1	69274
5	EX-99.2	a16-22208_1ex99d2.htm	EX-99.2	98444
6	EX-99.3	a16-22208_1ex99d3.htm	EX-99.3	35033
7	EX-99.4	a16-22208_1ex99d4.htm	EX-99.4	16002
8	EX-99.5	a16-22208_1ex99d5.htm	EX-99.5	9413
9	EX-99.6	a16-22208_1ex99d6.htm	EX-99.6	28812
10	EX-99.7	a16-22208_1ex99d7.htm	EX-99.7	14549
11	GRAPHIC	g222081ksi001.jpg	GRAPHIC	1252
12	GRAPHIC	g222081ksi002.gif	GRAPHIC	9224
13	GRAPHIC	g222081mo01i001.gif	GRAPHIC	1737
14	GRAPHIC	g222081mui001.gif	GRAPHIC	168510
15	GRAPHIC	g222081mui002.gif	GRAPHIC	169500
	Complete submission text file	0001104659-16-159611.txt		858748

Mailing Address LEBERSTRASSE 20 VIENNA C4 1110

Business Address LEBERSTRASSE 20 VIENNA C4 1110 43 (0)1 740 93-0

Nabriva Therapeutics AG (Filer) CIK: 0001641640 (see all company filings)